A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2098-2103

  Powles, T ^a   Kayani, I ^b   Sharpe, K ^a   Lim, L ^a   Peters, J ^a   Stewart, G D ^c   Berney, D ^a   Sahdev, A ^a   Chowdhury, S ^d   Boleti, E ^e   Boleti, J ^a   Reynolds, A R ^f   Jones, R ^g   Blank, C ^h   Haanen, J ^h   Bex, A ^h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

FDG PET; Intermittent treatment; Metastatic renal cancer; Nephrectomy; VEGF targeted therapy

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG THERAPY; FEMALE; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING;

FDG-PET; INTERMITTENT TREATMENT; METASTATIC RENAL CANCER; NEPHRECTOMY; VEGF-TARGETED THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEPHRECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RADIOPHARMACEUTICALS; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WITHHOLDING TREATMENT;

EID: 84881245872     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt130     Document Type: Article

References (18)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
2. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
3. Motzer RJ, Hutson TE, Reeves J, et al. Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial. Presented at the 37th Congress of the European Society for Medical Oncology (ESMO). Vienna, Austria, September 28-October 2, 2012. Abstract LBA8.
4. Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012; 30(5): 482-487.
5. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
6. Griffioen AW, Mans L, de Graaf A, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18(14): 3961-3971.
7. Desar IM, Mulder SF, Stillebroer AB, et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 2009; 48: 927-931.
8. Powles T, Blank C, Chowdhury S, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 2011; 60: 448-454.
9. Bex A, Blank C, Meinhardt W, et al. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 2011; 78: 832-837.
10. Boleti E, Sarwar N, Jones R, et al. The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. J Clin Oncol 2012; 30 (suppl 5); Abstract 427.
11. Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011; 17: 6021-6028.
12. Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2010; 106: 218-223.
13. O'Malley RL, Brewer KA, Hayn MH, et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?. Urology 2011; 78: 595-600.
14. Stewart G, O'Mahony R, Eory L, et al. Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. Clin Oncol 2012; 30 (Suppl 5); Abstract 388.
15. Welti JC, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 2012; 15(4): 623-641.
16. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol 2012; 30(12): 1371-1377.
17. Johannsen M, Staehler M, Ohlmann CH, et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol 2011; 22: 657-663.
18. Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT Trial. Presented at the 37th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, 2012. Abstract LBA22.